ArticleInternational journal of molecular sciences2022

Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Deletion but Not Inhibition of Extracellular PCSK9 Reduces Infarct Sizes Ex Vivo but Not In Vivo.

Rolf Schreckenberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.